Contrast Nephropathy

Febuxostat Reduces Contrast-Induced Acute Kidney Injury in Stage 3 CKD

Publish Date May 31, 2023

Patients with stage 3 chronic kidney disease are at increased risk for contrast-induced acute kidney injury.

Statins May Reduce Contrast-Induced Acute Kidney Injury

Publish Date November 4, 2022

Given the widespread use of contrast medium in cardiovascular and other imaging, continued focus on preventing contrast-induced acute kidney injury is warranted.

Post-Contrast Acute Kidney Injury Linked to Transient Hypotension

Publish Date September 28, 2022

Transient hypotension increases the risk for post-contrast acute kidney injury following computed tomography with contrast media, according to investigators.

Allopurinol May Reduce Contrast Nephropathy in CKD Population

Publish Date May 24, 2022

Previous research suggested that allopurinol, a xanthine oxidase inhibitor, prevents the formation of oxygen-free radicals that may contribute to contrast nephropathy.

Markers to Predict CI-AKI in Patients With ACS Undergoing Coronary Angiography

Publish Date November 5, 2020

BNP or NT-proBNP may represent effective markers for the prediction of contrast-induced acute kidney injury in patients with acute coronary syndrome undergoing coronary angiography.

Gadavist Imaging Bulk Package Approved for Multi-Patient Dosing

Publish Date August 19, 2020

Gadavist® Imaging Bulk Package is supplied as 604.72mg/mL of gadobutrol in 30mL and 65mL multidose containers.

Recommendations for Use of IV Iodinated Contrast Media Updated

Publish Date March 3, 2020

Radiologists and clinicians should weigh the relative benefits and risks of using IV contrast in patients with eGFRs less than 30 mL/min/1.73 m2, according to a consensus statement.

Renal Outcomes Not Worsened by Omitting Hydration Prior to Contrast-Enhanced CT

Publish Date February 20, 2020

Withholding prehydration with sodium bicarbonate from patients with CKD stage 3 undergoing nonemergent contrast-enhanced computed tomography does not compromise renal safety, a study found.

Data Support Group II Gadolinium-Based Contrast Use in Advanced Kidney Disease

Publish Date February 5, 2020

The potential diagnostic harms of withholding group II gadolinium-based contrast agents may outweigh the risk of nephrogenic systemic fibrosis in advanced CKD patients, according to investigators.

Hepcidin May Enable Early Ruling Out of Contrast-Induced AKI

Publish Date March 6, 2019

Serum hepcidin rises significantly as early as 4 and 8 hours after percutaneous coronary intervention.